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ABSTRACT: Previous studies of recombinant full-length human apolipoprotein A-V (apoA-V) provided
evidence of the presence of two independently folded structural domains. Computer-assisted sequence
analysis and limited proteolysis studies identified an N-terminal fragment as a candidate for one of the
domains. C-Terminal truncation variants in this size range, apoA-V(1-146) and apoA-V(1-169), were
expressed in Escherichia coli and isolated. Unlike full-length apoA-V or apoA-V(1-169), apoA-V(1-146)
was soluble in neutral-pH buffer in the absence of lipid. Sedimentation equilibrium analysis yielded a
weight-average molecular weight of 18811, indicating apoA-V(1-146) exists as a monomer in solution.
Guanidine HCl denaturation experiments at pH 3.0 yielded a one-step native to unfolded transition that
corresponds directly with the more stable component of the two-stage denaturation profile exhibited by
full-length apoA-V. On the other hand, denaturation experiments conducted at pH 7.0 revealed a less
stable structure. In a manner similar to that of known helix bundle apolipoproteins, apoA-V(1-146) induced
a relatively small enhancement in 8-anilino-1-naphthalenesulfonic acid fluorescence intensity. Quenching
studies with single-Trp apoA-V(1-146) variants revealed that a unique site predicted to reside on the
nonpolar face of an amphipathic R-helix was protected from quenching by KI. Taken together, the data
suggest the 146 N-terminal residues of human apoA-V adopt a helix bundle molecular architecture in the
absence of lipid and, thus, likely exist as an independently folded structural domain within the context of
the intact protein.
Hypertriglyceridemia (HTG)1 is strongly and positively
correlated with susceptibility to atherosclerosis (1). Further-
more, HTG is a risk factor for development of the metabolic
syndrome and the accompanying insulin resistance, hyper-
tension, obesity, and inflammation. On this basis, there is
considerable interest in understanding factors that regulate
plasma triglyceride (TG) levels. The discovery of a new
apolipoprotein in 2001, termed apolipoprotein (apo) A-V,
has sparked an intensive research effort (2, 3). The impact
of apoA-V on plasma TG levels is vividly illustrated by the
seminal report of Pennacchio et al. (4). Using genetically
modified mice, these authors showed that plasma TG
concentrations in human APOA5 transgenic mice were 3-fold
lower than those of control littermates. At the same time,
apoA-V gene-disrupted mice exhibited a 4-fold increase in
plasma TG concentration.
Human apoA-V is synthesized in the liver as a 366-amino
acid preprotein. Following cleavage of a 23-amino acid signal
peptide, mature apoA-V, consisting of 343 residues, can be
detected in plasma (5). Comparative sequence analysis
indicates apoA-V is a member of the class of exchangeable
apolipoproteins and predicts a hydrophobic protein with a
significant amount of R-helical secondary structure (6). This
prediction has been confirmed by far-UV circular dichroism
spectroscopy analysis (7). A distinguishing feature of re-
combinant lipid-free apoA-V is poor solubility in neutral-
pH buffer (8). Characterization studies of lipid-free apoA-V
revealed strong lipid binding activity (6). Consistent with
this, apoA-V is found exclusively associated with lipoproteins
in the plasma compartment. In mice, apoA-V is predomi-
nantly associated with HDL (9), while in humans, it is found
in the VLDL and HDL fractions (10). Evidence suggests
that apoA-V can exchange between VLDL and HDL, pos-
sibly as a function of plasma lipoprotein homeostasis (9).
In 2005, Marc¸ais et al. reported the presence of a mutant
form of apoA-V in a family with HTG (11). The mutation
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introduces a premature stop codon, resulting in a truncated
apoA-V variant that is recovered in the lipoprotein-deficient
fraction of plasma. These data suggest the C-terminal portion
of apoA-V is a determinant of its lipoprotein binding ability.
Subsequent studies revealed the C-terminus contributes to
the lipid binding activity of apoA-V (7). It was reported that
deletion of the 51 C-terminal amino acids from apoA-V
resulted in a variant protein that exhibited lower lipid binding
activity yet still possessed two independently folded structural
domains. In this study, we sought to define the boundary
between these domains and to characterize the N-terminal
domain in isolation. The results obtained reveal that lipid-
free apoA-V(1-146) adopts a relatively stable, monomeric,
asymmetric tertiary fold that is consistent with an amphip-
athic R-helix bundle.
MATERIALS AND METHODS
Site-Directed Mutagenesis and OVerexpression of Recom-
binant Proteins. Recombinant human apoA-V and C-terminal
truncation variants were produced in Escherichia coli and
isolated as described previously (8). The apoE NT domain
was prepared as described by Fisher et al. (12), and
apolipophorin III was prepared as described by Ryan et al.
(13). Site-directed mutagenesis was performed with the
QuikChange II XL site-directed mutagenesis kit (Stratagene).
Primers were designed to introduce a premature stop codon
or to substitute Trp5 with Phe and Trp97 with Phe or
substitute Leu73 of null apoA-V(1-146) with Trp. In all
cases, introduction of the desired mutations was verified by
DNA sequencing.
Limited Proteolysis. Aliquots of full-length apoA-V (0.1
mg/mL) in 50 mM sodium citrate (pH 3.0) and 150 mM
NaCl were incubated with 0.1 µg/mL porcine gastric pepsin
(Sigma) at 22 °C for up to 2 h. The reaction was stopped by
addition of SDS-PAGE sample treatment buffer and the
fragmentation pattern assessed by SDS gel electrophoresis
on a Tricine, 10 to 20% acrylamide slab run at a constant
125 V for 1.5 h and stained with Gel Code Blue (Pierce
Chemical Co.). Where indicated, separated protein fragments
were electrophoretically transferred to a PVDF membrane
and then subjected to N-terminal sequencing analysis (Mo-
lecular Structure Facility, University of California, Davis,
CA).
Analytical Procedures. Protein concentrations were de-
termined with the bicinchoninic acid assay (Pierce Chemical
Co.) using bovine serum albumin as the standard.
Analytical Ultracentrifugation. Sedimentation equilibrium
experiments were conducted at 20 °C in a Beckman XL-I
analytical ultracentrifuge using interference optics, as de-
scribed by Laue and Stafford (14). Aliquots (110 µL) of the
sample solution were loaded into six-sector CFE sample cells,
allowing three concentrations to be run simultaneously. Runs
were performed at three different speeds, and each speed
was maintained until there was no significant difference in
r2/2 versus absorbance scans taken 2 h apart to ensure that
equilibrium was achieved. Sedimentation equilibrium data
were evaluated using the NONLIN program, which employs
the nonlinear least-squares curve fitting algorithm described
by Johnson et al. (15). The protein’s partial specific volume
and the solvent density were estimated using Sednterp (16).
Sedimentation velocity experiments were conducted at 40000
rpm and 20 °C using absorbance optics. Runs were per-
formed at loading concentrations of 0.55 and 0.24 mg/mL.
Up to 260 scans were performed during the run. A
sedimentation coefficient value was obtained by analyzing
10 sets of data selected between the 160th and 205th scans
using Svedberg. From the amino acid composition, a
hydration value of 0.44 was obtained, assuming that all
charged groups are exposed.
Circular Dichroism Spectroscopy. Circular dichroism (CD)
measurements were performed on an AVIV 410 spectro-
photometer or a Jasco 810 spectropolarimeter. Far-UV CD
scans were recorded between 185 and 260 nm in 20 mM
sodium phosphate (pH 7.4) using a protein concentration of
0.5 mg/mL determined by the absorbance at 280 nm. The
R-helical content was calculated with the self-consistent
method using Dicroprot, version 2.6 (17). For guanidine HCl
denaturation studies, protein samples were dissolved in 50
mM citrate (pH 3.0) or 20 mM sodium phosphate (pH 7.4).
ApoA-V samples (0.2 mg/mL) were incubated overnight at
a given denaturant concentration to attain equilibrium, and
ellipticity was measured at 222 nm.
Fluorescence Spectroscopy. Fluorescence spectra were
recorded on a Horiba Jobin Yvon FluoroMax-4 luminescence
spectrometer. Protein (100 µg/mL) was dissolved in either
50 mM citrate (pH 3.0) with 150 mM NaCl or 20 mM
sodium phosphate (pH 7.4) with 150 mM NaCl. Samples
were excited at 295 nm, and emission was collected from
300 to 450 nm (2.0 nm slit width). Spectra of 8-anilino-1-
naphthalenesulfonic acid (ANS) solutions (250 mM) were
obtained in pH 7.4 buffer alone and in the presence of
specified proteins at 50 µg/mL. Samples were excited at 395
nm with emission monitored from 400 to 600 nm (2.0 nm
slit width). Since ANS fluorescence in buffer is negligible
(18), spectra were recorded in the presence of a minimum
100-fold excess of ANS with respect to protein (molar ratio).
For KI quenching studies, protein samples were excited at
295 nm and emission was monitored at their λmax values.
The solution of KI contained 1 mM sodium thiosulfate to
prevent formation of free iodine, and all readings were
corrected for dilution. The data were analyzed using the
Stern-Volmer equation: F0/F ) 1 + KSV[Q], where F0 and
F represent the emission intensity maximum in the absence
and presence of quencher, respectively. The collisional
quenching constant (KSV) was determined from the initial
slope of plots of F0/F versus [Q].
RESULTS
Limited Proteolysis of Full-Length ApoA-V. On the basis
of similarities with other members of the exchangeable
apolipoprotein family (19, 20), we hypothesized that the
N-terminus of apoA-V may exist in solution as an indepen-
dently folded, amphipathic R-helix bundle. In the case of
another two-domain apolipoprotein, apoE, limited proteolysis
yielded two major fragments (21, 22) that were shown to
exist as independently folded structural domains (23, 24).
Due to the insolubility of lipid-free full-length apoA-V at
neutral pH, proteolytic digestion experiments were conducted
at pH 3.0 using pepsin. Isolated recombinant apoA-V was
incubated with pepsin (1000:1, w/w) as a function of time,
followed by SDS-PAGE analysis of the digestion products
(Figure 1). The data showed that, as intact apoA-V was
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rapidly degraded, two prominent fragments, one of ∼22 kDa
and the other of ∼18 kDa, were generated. At longer time
points, or higher protease concentrations, complete degrada-
tion of apoA-V occurred (data not shown). On the basis of
the apparent protection of the 18 and 22 kDa fragments from
limited proteolysis, these fragments were subjected to further
characterization. Electrospray ionization mass spectrometry
analysis yielded molecular mass values of 18721.2 and
22198.9 Da. N-Terminal sequencing of the cleavage products
revealed the first 7-10 amino acid residues of the 18 kDa
band correspond to V-S-G-I-G-R-H-V-Q-E-L, while that for
the 22 kDa band was M-H-H-H-H-H-H. Since recombinant
apoA-V employed in the proteolysis studies possessed an
N-terminal His-tag extension, we conclude that the larger
cleavage product corresponds to the N-terminal portion of
apoA-V (residues 1-175). The identity of the smaller 18
kDa band corresponds to apoA-V residues 176-343, pre-
sumably encompassing the C-terminal structural domain of
apoA-V.
In Silico Analysis of the ApoA-V N-Terminal Domain.
Evaluation of the N-terminal sequence of apoA-V (residues
1-175) with Coils (25) predicts that residues Ala31-Arg52,
Val67-Gln85, and Asp112-Asp134 adopt R-helix second-
ary structure. Given that a hallmark feature of the class of
exchangeable apolipoproteins is the presence of amphipathic
R-helices approximately 22 amino acids in length, we sought
to assess if these predicted helices would display amphipathic
character [i.e., possess distinct nonpolar and polar faces with
positively charged amino acids located at the interface
between the polar and nonpolar faces, while negatively
charged residues reside at the apex of the polar face (26)].
An Edmundson wheel (27) projection of the sequence from
Gly68 to Gln85 reveals these characteristic features (Figure
2) consistent with earlier hydropathy analysis (6). Further-
more, similar to other members of the class of exchangeable
apolipoproteins, two of the three R-helix segments predicted
with Coils are punctuated by proline residues (Figure 3).
Isolation and Characterization of ApoA-V(1-146). In an
effort to study the N-terminal fragment of apoA-V in greater
detail, two truncation variants, apoA-V(1-169) and apoA-
V(1-146), were expressed in E. coli, isolated, and character-
ized (Figure 4). ApoA-V(1-292) was previously character-
ized and found to possess two structural domains (7). Unlike
full-length apoA-V, apoA-V(1-292), or apoA-V(1-169),
apoA-V(1-146) was soluble in aqueous buffer at neutral
pH. Furthermore, limited proteolysis experiments with apoA-
V(1-146) revealed resistance to further degradation. Given
the favorable solubility properties of this variant and the
apparent similarity of this truncated apoA-V variant to one
of the protease resistant fragments generated upon pepsin
treatment of full-length apoA-V, characterization studies of
apoA-V(1-146) were performed.
Hydrodynamic Properties. The hydrodynamic properties
of apoA-V(1-146) were investigated by sedimentation
equilibrium analyses performed at pH 7.0 (Table 1). The
initial centrifugation speed was set at 22000 rpm, and
equilibrium was reached after 18 h. Data were collected at
22000, 24000, and 26000 rpm. The apparent average
molecular mass of apoA-V(1-146) was 18811 Da, a value
that corresponds well with the calculated molecular mass of
this protein (18795 Da). These data indicate that, unlike full-
length apoA-V (8), apoA-V(1-146) exists in solution as a
monomer. To evaluate the shape of apoA-V(1-146) in
solution, sedimentation velocity experiments were conducted.
Using Svedberg, the data were fit to a single-species model
yielding a sedimentation coefficient of ∼1.8. Sednterp was
then used to calculate an axial ratio value. Using a prolate
model and a hydration expansion of 17.1%, an axial ratio
(a/b) of 7 was obtained.
CD Spectroscopy and Stability Studies. Far-UV CD
spectroscopy of apoA-V(1-146) at pH 7.4 yielded a
spectrum with minima at 208 and 222 nm. Deconvolution
of the spectra yielded an R-helix secondary structure content
of 40.4%, consistent with predictions from Coils analysis.
To assess the stability properties of apoA-V(1-146) in
solution, the effects of guanidine HCl concentration on
ellipticity values at 222 nm were determined (Figure 5). At
pH 3.0 (pH at which comparisons with data on full-length
apoA-V can be made), as the concentration of denaturant
increased form 0 to 4 M, apoA-V(1-146) unfolded in a
single transition, with a midpoint at 2.0 M guanidine HCl.
At pH 7.4, although apoA-V(1-146) still undergoes a one-
step nativef unfolded transition, the transition midpoint is
shifted to 0.9 M guanidine HCl, a value similar to that
reported for apoA-I (28).
Fluorescent Dye Binding Studies. ANS, a hydrophobic
fluorescent dye, binds to exposed hydrophobic surfaces in
proteins (18). In the absence of protein, ANS has a very low
FIGURE 1: SDS-PAGE analysis of pepsin-limited proteolysis of
full-length apoA-V. Proteins were electrophoresed on a 10 to 20%
acrylamide-SDS slab gel and stained with Gel Code Blue reagent:
lane 1, untreated full-length apoA-V; lane 2, molecular mass
markers; lane 3, pepsin-treated full-length apoA-V at 0 min; lane
4, pepsin treated for 5 min; lane 5, pepsin treated for 30 min; lane
6, pepsin treated for 60 min; and lane 7, pepsin treated for 120
min. NT denotes the N-terminal fragment and CT the C-terminal
fragment.
FIGURE 2: Helical wheel diagram for a predicted helix in apoA-
V(1-146). The amino acid residues depicted are numbered with
hydrophobic residues circled in bold and charged residues indicated.
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quantum yield with an emission wavelength maximum of
∼520 nm (excitation at 395 nm). Albumin, a serum lipid
transport protein known to possess exposed hydrophobic lipid
binding sites, induced a significant enhancement in ANS
fluorescence intensity as well as a blue shift in the wave-
length of maximum fluorescence emission at pH 7.4 (Figure
6). By contrast, known helix bundle apolipoproteins, includ-
ing apoE3 NT (29) and apolipophorin III (30), had a weaker
effect on ANS fluorescence intensity. In a similar manner,
apoA-V(1-146) induced a relatively small enhancement in
ANS fluorescence intensity, consistent with sequestration of
hydrophobic sites in this protein from the aqueous milieu.
Tryptophan Fluorescence Emission of ApoA-V(1-146)
Variants. ApoA-V(1-146) has two naturally occurring Trp
residues, located at positions 5 and 97. Fluorescence emission (excitation at 295 nm) spectra of wild-type apoA-V(1-146)
gave rise to a λmax of 350 nm (Table 2). To determine the
individual contribution of the two Trp residues in this protein,
single-Trp variant apoA-V(1-146) forms were generated.
To test the hypothesis that apoA-V(1-146) adopts a helix
bundle conformation in solution, a single Trp was also
introduced into Trp-null apoA-V(1-146) by replacing Leu73
with Trp. On the basis of predictions, this sequence position
should reside on the nonpolar face of an amphipathic R-helix
(see Figure 2). At neutral pH, the λmax of each of the three
single-Trp variants was 349 nm. In contrast, when Trp
fluorescence emission was monitored at pH 3.0, both the
Trp73 and Trp97 variants show a blue shift in λmax to 338
and 341 nm, respectively (Table 2).
Fluorescence Quenching. To obtain additional information
about the local environments of Trp5, Trp97, and Trp73 in
single-Trp apoA-V(1-146) variants, fluorescence quenching
studies were performed with potassium iodide (KI) as the
FIGURE 3: Amino acid sequence of apoA-V(1-146). Residues postulated to adopt R-helical secondary structure, as predicted with Coils
analysis, are underlined. Proline residues are depicted in bold.
FIGURE 4: SDS-PAGE analysis of isolated apoA-V truncation
variants: lane 1, molecular mass markers; lane 2, full-length apoA-
V; lane 3, apoA-V(1-292); lane 4, apoA-V(1-169); and lane 5,
apoA-V(1-146).
Table 1: Result Summary of Sedimentation Velocity Runs on
ApoA-V(1-146)
sample
concentration (mg/mL) S20,w S°20,w axial ratio
0.55 1.868 1.877 6.385
0.24 1.756 1.760 7.883
FIGURE 5: Guanidine HCl denaturation of apoA-V(1-146). The
molar ellipticity of the protein was measured at 222 nm at a
concentration of 0.2 mg/mL in 50 mM citrate and 150 mM NaCl
(pH 3.0) (O) or 20 mM phosphate buffer (pH 7.4) (b), at various
concentrations of guanidine HCl ((standard deviation; n ) 4).
FIGURE 6: Effect of proteins on ANS fluorescence: (a) albumin,
(b) apoA-V(1-146), (c) apoLp III, (d) apoE3 NT, and (e) ANS in
buffer.
Table 2: Fluorescence Properties of ApoA-V(1-146) Single-Trp
Variantsa
λmax (nm)b
pH 7.4 pH 3.0
“wild type” 350 347
Trp5 349 348
Trp97 349 341
Trp73 349 338
a Spectra were recorded on a Horiba Jobin Yvon FluoroMax-4
luminescence spectrometer. Emission was scanned from 300 to 450 nm
(excitation at 295 nm; 2.0 nm slit width for the excitation and emission
monochromators). All spectra were recorded in either 20 mM sodium
phosphate (pH 7.4) with 150 mM NaCl or 50 mM sodium citrate (pH
3.0) with 150 mM NaCl. b λmax is the wavelength of maximum
fluorescence emission. Values are the means of three determinations. In
all cases, the standard deviations were e1 nm.
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quenching agent. Stern-Volmer plots for each single-Trp
variant were linear (Figure 7), and KSV constants were
obtained from the slope of the plots. The values were 3.2
M-1 for the Trp5 variant, 2.2 M-1 for the Trp97 variant,
and 1.8 M-1 for the Trp73 variant.
DISCUSSION
The amphipathic R-helix bundle is a common structural
motif among exchangeable apolipoproteins in their lipid-free
state. X-ray crystallography studies of the apoE NT domain
(29), apolipophorin III (31), and apoA-I (20) reveal elongated
up-and-down bundles of four or five amphipathic R-helices.
In every case, the helices orient such that their hydrophobic
faces are directed toward the bundle interior. At the same
time, hydrophilic moieties are directed to the solvent,
conferring aqueous solubility to these proteins (32). In this
study, the data are consistent with the presence of at least
three distinct R-helices in apoA-V(1-146). Whereas the
three-helix bundle motif exists among helix bundle proteins
in general (33–35), no three-helix bundle motifs have been
reported for apolipoproteins. Evidence of the presence of only
three helix segments in apoA-V(1-146) is based upon
predictions from Coils analysis. However, caution must be
exercised in this case since a similar analysis of human apoE3
N-terminal domain primary structure predicts residues 1-183
also possess three distinct helix segments. Whereas Coils
analysis faithfully predicts the boundaries for three of the
four known helices [on the basis of X-ray crystallography
(29)] to exist in the apoE NT domain, helix 1 was not
identified with this program. On the basis of this, it is
conceivable that apoA-V(1-146) may possess a fourth helix
segment that was simply not predicted by Coils analysis.
Given the location of the three identified helix segments, a
fourth helix, if present, could be located at the extreme
N-terminus of this truncated apoA-V or between proline
residues 86 and 108, consistent with fluorescence quenching
data of Trp97. In fact, apoA-V(1-146) could conceivably
contain five amphipathic helices, which has been shown with
apolipophorin III (30, 31). The actual tertiary organization
of the apoA-V NT domain will require detailed high-
resolution structure data from NMR spectroscopy and/or
X-ray crystallography.
On the basis of structural studies and other evidence,
hypotheses have been proposed to explain the lipid surface
seeking behavior of helix bundle apolipoproteins. Thus,
whereas hydrophobic helix-helix interactions contribute to
stabilization of the bundle conformation, these interactions
are replaced by helix-lipid interactions in a lipid-associated
state. Such a transition, however, requires that the bundle
undergo conformational “opening” to expose hydrophobic
lipid binding sites in the protein interior (19, 20, 36). Several
lines of evidence are consistent with this hypothesis, and in
the case of the apoE NT domain, this transition plays a key
role in manifestation of its low-density lipoprotein receptor
recognition properties (37). Given the evidence that apoA-
V(1-146) adopts a helix bundle motif, it is likely that a
similar transition occurs upon association of lipid with this
protein.
In certain helix bundle apolipoproteins, the helix bundle
motif constitutes the sole structural element of the protein
(30, 31). In other cases, however, the helix bundle motif
exists as a domain in the context of a larger protein. Thus,
for example, apoE exists as a two-domain protein comprised
of an N-terminal helix bundle and a C-terminal lipid binding
domain (19). Likewise, the N-terminus of apoA-I adopts a
helix bundle that is connected to a short C-terminal segment
with high lipid binding affinity (20). Given the relatively
large size of apoA-V and the results of guanidine HCl
denaturation studies (7), it is evident that two independently
folded structural domains are present. Furthermore, recent
studies with another C-terminal truncation variant, apoA-
V(1-292), provided evidence that the N-terminus comprises
the more stable component of the two structural elements in
apoA-V (7). In the case of apoE, the 165 N-terminal amino
acids adopt a four-helix bundle conformation (38). From
denaturation data, primary sequence analysis, and limited
proteolysis, it may be concluded that the N-terminus of
apoA-V adopts a similar molecular architecture in the
absence of lipid. Indeed, several lines of evidence indicate
that the 146 N-terminal amino acids of apoA-V exist as a
helix bundle. Evidence supporting this interpretation includes
the solubility properties of apoA-V(1-146). Whereas full-
length apoA-V and truncation variants longer than 146
residues are insoluble in neutral-pH buffer, this is not the
case for apoA-V(1-146). In general, it is envisioned that
solubility is conferred to helix bundle apolipoproteins because
of their ability to sequester hydrophobic lipid binding sites
in the bundle interior. Because of this, isolated helix bundle
apolipoproteins often exist in solution in a monomeric state
(24). In the case of apoA-V(1-146), sedimentation equilib-
rium experiments provide evidence that the protein exists in
solution as a monomer, and consistent with other helix bundle
apolipoproteins, sedimentation velocity experiments yielded
an axial ratio value that is consistent with a highly asym-
metric structure. Similar values have been reported for helix
bundle apolipoproteins (39), and these findings are supported
by high-resolution structure data (20, 29–31).
An ability of helix bundle apolipoproteins to sequester their
hydrophobic lipid binding sites in the bundle interior is
generally manifest by a weaker ability to enhance the
fluorescence signal of ANS relative to proteins known to
have exposed hydrophobic sites (40). ApoA-V(1-146)
behaved like apolipophorin III and the apoE3 NT domain,
suggesting it too adopts a helix bundle structure. On the basis
FIGURE 7: Trp fluorescence quenching of apoA-V(1-146) by KI
at pH 7.4. Stern-Volmer plots of apoA-V(1-146) Trp5 (O), apoA-
V(1-146) Trp97 (b), and apoA-V(1-146) Trp73 (0).
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of Coils analysis, the Trp at position 5 is predicted to be
solvent-exposed. Fluorescence quenching studies with KI at
pH 7.4 show Trp5 is more susceptible to quenching,
consistent with its location at the extreme N-terminus of the
protein. On the other hand, Trp73 is anticipated to reside on
the hydrophobic face of an amphipathic R-helix on the basis
of Coils and Edmundson wheel analyses. The λmax of Trp73
at 338 nm (at pH 3.0) suggests it resides in a more nonpolar
environment under these conditions. KI quenching studies
with apoA-V(1-146) Trp73 reveal the Trp at this position
is relatively protected from this quencher, providing ad-
ditional evidence of its proposed location within a helix
bundle. KI quenching shows Trp97 to be more protected
from the quencher than Trp5 but not more than Trp73. Thus,
it is conceivable that the region encompassing Trp97 adopts
amphipathic R-helix secondary structure. While Trp73 was
the least susceptible to fluorescence quenching, it was not
completely inaccessible, which along with the Trp fluores-
cence emission results and the denaturation studies at pH
7.4, implies that the apoA-V NT domain at neutral pH may
adopt a “loosely” folded helix bundle under physiological
conditions. Given the greater propensity of molten globule-
like conformations in apolipoproteins to associate with lipid
surfaces (41), this property may be relevant to the function
of this structural element in apoA-V, possibly in concert with
the C-terminal region of intact apoA-V.
At present, it is unknown if the NT domain of apoA-V
alone is capable of manifesting biological effects seen with
full-length apoA-V. On the basis of results of studies of a
mutant and/or truncated form of apoA-V in human subjects
that is associated with severe HTG (11), this segment of the
protein alone may not be sufficient to manifest the biological
effects seen with apoA-V in genetically engineered mice.
Indeed, previous studies have suggested that residues in the
region of residues 186-242 in apoA-V are responsible for
the heparin binding ability of apoA-V (42) as well as its
function as a ligand for members of the low-density
lipoprotein receptor family (43) or recently identified gly-
cosylphosphatidylinositol high-density lipoprotein binding
protein 1 (44). Adenovirus-mediated gene transfer of apoA-
V(1-146) into apoA-V gene-disrupted mice will permit this
question to be addressed.
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